Alkermes plc (ALKS) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Alkermes plc Reports Third Quarter 2015 Financial Results
October 29, 2015 7:02 AM EDTThird Quarter Revenues of $152.7 Million and Non-GAAP Diluted Loss Per Share of $0.18
Commercial Launch of ARISTADA Underway Following FDA Approval for the Treatment of Schizophrenia on Oct. 5, 2015
ALKS 3831 for Schizophrenia and ALKS 8700 for Multiple Sclerosis to Commence Registration Studies Before Year-End
DUBLIN--(BUSINESS WIRE)-- Alkermes plc (NASDAQ: ALKS) today reported financial results for... More
